Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 24, 2026Endocrinology Diabetes & MetabolismOpen Access

Tirzepatide demonstrated significant improvements in symptoms, cardiac function, and reverse remodeling in obesity-related heart failure patients compared to placebo.

View Full Paper
Ask AI
Bookmark
Share

Key result

Tirzepatide demonstrated significant improvements in symptoms, cardiac function, and reverse remodeling in obesity-related heart failure patients compared to placebo.

Authors

HAHamza A Abdul-HafezAAAmeer AwashraSBSosana Bdir

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Abdul-Hafez et al. (2026) studied this question. Tirzepatide demonstrated significant improvements in symptoms, cardiac function, and reverse remodeling in obesity-related heart failure patients compared to placebo.

synapsesocial.com/papers/697567b7a97bda96496bd596https://doi.org/10.1002/edm2.70152
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity2025
  2. 2Tirzepatide and Gut Microbiome: A Narrative Review of Current Evidence and Future Implications2025
  3. 3Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis2025
  4. 4OBESITY MANAGEMENT - A COMPARATIVE REVIEW OF THE EFFICACY AND SAFETY OF BARIATRIC SURGERY AND TIRZEPATIDE THERAPY2025
  5. 5Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study2026